Home › Research › Biomarkers
Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients
Shinomoto M, Kasai T, Tatebe H, Kondo M, Ohmichi T, Morimoto M, Chiyonobu T, Terada N et al.. PloS one, 2019-04-05
Topic: Brain proteins, microglia and lab models
Plain-language summary
People with Down syndrome (DS) are at high risk of developing Alzheimer disease (AD) with aging. The diagnosis and treatment trials are hampered by a lack of reliable blood biomarkers. Plasma neurofilament light chain (NfL) is one of the established biomarkers of AD, suggesting that it may be useful as an indicator of dementia in DS patients. The aims of this study were: 1) to examine whether plasma levels of NfL in DS patients are correlated with decreased adaptive behavior scores one year after sample collection, and 2) to compare plasma levels of NfL in adults with DS and an age-matched healthy control population. In this study, plasma levels of NfL in 24 patients with DS and 24 control participants were measured by the single-molecule immunoarray (Simoa) method. We observed significantly increased plasma NfL levels in the DS compared with the control group. There was a significant correlation between age and levels of plasma NfL in both groups. This age-dependent elevation was steeper in the DS compared with the control group. Moreover, elevated plasma NfL was associated with decreased adaptive behavior scores one year later, after age-adjustment. Previously reported blood-based biomarkers available in Simoa for DS, plasma total tau and phosphorylated tau, were not significantly correlated with the annual decrement of adaptive behavior scores after age-adjustment. These results suggest that plasma NfL has the potential to serve as an objective biomarker to predict dementia in adult DS patients.
What this study adds
Evidence grade: Low
The record lists 24 participants. In 24 adults with Down syndrome and 24 controls, plasma neurofilament light was higher in the Down syndrome group and higher levels were linked to decreased adaptive behavior one year later. This is a small study suggesting a possible prognostic blood marker, not a treatment or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Shinomoto, M., Kasai, T., Tatebe, H., Kondo, M., Ohmichi, T., Morimoto, M., et al. (2019). Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients. PloS one. https://doi.org/10.1371/journal.pone.0211575
Vancouver
Shinomoto M, Kasai T, Tatebe H, Kondo M, Ohmichi T, Morimoto M, et al. Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients. PloS one. 2019. doi:10.1371/journal.pone.0211575. PMID: 30951523.
BibTeX
@article{shinomoto2019-30951523,
author = {Shinomoto, M. and Kasai, T. and Tatebe, H. and Kondo, M. and Ohmichi, T. and Morimoto, M. and Chiyonobu, T. and Terada, N. and others},
title = {{Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients}},
journal = {PloS one},
year = {2019},
doi = {10.1371/journal.pone.0211575},
pmid = {30951523},
url = {https://doi.org/10.1371/journal.pone.0211575}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Plasma neurofilament light chain (NfL) is one of the established biomarkers of AD, suggesting that it may be useful as an indicator of dementia in DS patients.
- We observed significantly increased plasma NfL levels in the DS compared with the control group.
- There was a significant correlation between age and levels of plasma NfL in both groups.
- This age-dependent elevation was steeper in the DS compared with the control group.
- Moreover, elevated plasma NfL was associated with decreased adaptive behavior scores one year later, after age-adjustment.
Why it matters
In 24 adults with Down syndrome and 24 controls, plasma neurofilament light was higher in the Down syndrome group and higher levels were linked to decreased adaptive behavior one year later. This is a small study suggesting a possible prognostic blood marker, not a treatment or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants24
- Evidence strengthLow
How this study scored 46/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (PloS one) |
| Journal's citation record | 4 / 4 | PLoS ONE: journal h-index 594 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 1 / 4 | 24 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 31 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.4 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 3 / 6 | Cited 4.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 1 / 4 | Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Takahiko Tokuda: h-index 49 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Lancaster University: institution h-index 694 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 30951523) |
| Free to read | 2 / 2 | Free to read |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1371/journal.pone.0211575
- PubMed: 30951523
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Biomarkers from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.